Annovis Bio's Alzheimer's Drug Trial 65% Enrolled, Patent Extended to 2047
Summary
Annovis Bio announced significant corporate updates, including reaching 65% enrollment in its pivotal Phase 3 Alzheimer's disease (AD) clinical trial for buntanetap. The company also reported a positive Data and Safety Monitoring Board (DSMB) recommendation for the drug's safety and initiated an open-label extension study for Parkinson's disease (PD), with positive FDA feedback for a new PD dementia study. Crucially, Annovis extended the intellectual property protection for buntanetap until 2047 through a new crystal form. This operational progress provides a positive counterpoint to the recent 10-K filing on March 13, 2026, which raised concerns about the company's going concern status and NYSE listing. The substantial clinical trial progress and extended patent life are material developments for a clinical-stage biotech, potentially improving its long-term outlook. Traders will closely watch for further enrollment updates, clinical data readouts, and any developments regarding the company's financial position.
At the time of this announcement, ANVS was trading at $2.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $66.8M. The 52-week trading range was $1.11 to $5.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: EQS.